Q2 2026 Sarepta Therapeutics Inc Earnings Call Transcript
Key Points
- Sarepta Therapeutics Inc (SRPT) delivered another quarter of GAAP and non-GAAP operating profitability, reflecting the durability of its base business and disciplined execution.
- The company increased its cash and investments by approximately $197 million during the quarter, strengthening its ability to fund future growth independently.
- The PMO franchise remains stable with sustained patient and physician confidence, supported by extensive real-world evidence and adherence rates exceeding 90%.
- The FDA accepted the supplemental new drug applications for Amondis 45 and Viondis 53, seeking conversion to traditional approvals with a PDUFA date of February 28, 2027.
- The company's siRNA platform shows promise, with early clinical data demonstrating high muscle concentration and robust target engagement, positioning it for potential best-in-class therapies in FSHD and DM1.
- Enrollment form activity for Elevidus improved quarter-over-quarter, providing early evidence that expanded commercial initiatives are taking hold and rebuilding confidence in the Duchenne community.
- Sarepta Therapeutics Inc (SRPT) narrowed its 2026 total net product revenue guidance to $1.2 billion to $1.3 billion, with the midpoint being the appropriate reference, reflecting a trend toward the lower end of the original range.
- Elevidus revenue in the second half of 2026 is expected to be modestly lower than the first half, with third-quarter revenue expected to trend lower than Q2 due to the timing of patient conversions.
- The company faces concerns regarding Elevidus adoption and potential competition on the horizon for exon skipping treatments, which could impact future market share.
- The company recorded a $39 million litigation contingency charge in the quarter to potentially resolve certain outstanding patent claims.
- The ENDEAVOR Cohort 8 data, which is critical for the non-ambulatory Elevidus indication and the LGMD program, has been delayed to the first quarter of 2027, later than initially expected.
- Total revenues decreased 34% year-over-year in the second quarter, driven primarily by lower Elevidus demand.
Good afternoon, and welcome to Sarepta's second quarter 2026 earnings results call. As a reminder, today's program is being recorded. At this time, I'll turn the call over to Tam Thornton, Sarepta's Senior Director of Investor Relations. Please go ahead.
Thank you, and thank you all for joining today's call. Earlier this afternoon, we released our financial results for the second quarter of 2026.
The press release, along with our slides and supplementary information, are available on the Investors section of our company website. We plan to file a Form 10-Q for the quarter today with the SEC. Joining me on the call are Michael Severino, our CEO.
Dr. Louise Rodino Claypack, President of R&D and Technical Operations, Patrick Moss, our Chief Commercial Officer, and Ryan Wong, our Chief Financial Officer. Additionally, joining us in the Q&A portion of the call are Ian Estepan, President and Chief Operating Officer, and Dr. James Richardson, Chief Medical Officer.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
